Market overview
The global early pulmonary embolism thrombectomy device market is worth USD 935 mn in 2026 and is forecast to reach USD 2.9 bn by 2036, growing at a 12.0% CAGR. United States is the largest country market and Large-bore mechanical aspiration is the largest by technology segment.
| Scope | Catheter systems that remove clot from the lung arteries by mechanical or vacuum aspiration, used in intermediate-risk, high-risk and early-stage pulmonary embolism. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 820 mn |
| Value 2026 | USD 935 mn |
| Value 2036 | USD 2.9 bn |
| CAGR 2026-2036 | 12.0% |
| Volume 2026 | 63.3 thousand procedures |
| Volume 2036 | 218 thousand procedures |
| Average price 2026 | USD 14,760 per procedure |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Early Pulmonary Embolism Thrombectomy Device market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 935 mn |
| 2027 | USD 1.0 bn |
| 2028 | USD 1.2 bn |
| 2029 | USD 1.3 bn |
| 2030 | USD 1.5 bn |
| 2031 | USD 1.6 bn |
| 2032 | USD 1.8 bn |
| 2033 | USD 2.1 bn |
| 2034 | USD 2.3 bn |
| 2035 | USD 2.6 bn |
| 2036 | USD 2.9 bn |
Early Pulmonary Embolism Thrombectomy Device market segmentation
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Large-bore mechanical aspiration | 66.0% | 63.0% | USD 617 mn | 11.5% |
| Computer-assisted vacuum aspiration | 22.0% | 28.6% | USD 206 mn | 15.0% |
| Rheolytic and other | 12.0% | 8.3% | USD 112 mn | 8.0% |
By patient risk
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Intermediate risk | 58.0% | 56.9% | USD 542 mn | 11.8% |
| High risk | 24.0% | 18.0% | USD 224 mn | 8.8% |
| Early and low-risk | 18.0% | 25.1% | USD 168 mn | 15.8% |
By catheter bore
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Large bore above 20 Fr | 52.0% | 48.0% | USD 486 mn | 11.1% |
| Mid bore 14 to 20 Fr | 30.0% | 32.0% | USD 280 mn | 12.7% |
| Small bore below 14 Fr | 18.0% | 20.0% | USD 168 mn | 13.2% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Academic medical centres | 40.0% | 36.0% | USD 374 mn | 10.8% |
| Large community hospitals | 38.0% | 38.0% | USD 355 mn | 12.0% |
| Specialty cardiovascular centres | 22.0% | 26.0% | USD 206 mn | 13.9% |
By operator
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Interventional cardiologists | 42.0% | 40.0% | USD 393 mn | 11.4% |
| Interventional radiologists | 34.0% | 34.0% | USD 318 mn | 12.0% |
| Vascular surgeons | 24.0% | 26.0% | USD 224 mn | 12.9% |
Top 25 countries for early pulmonary embolism thrombectomy device by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 93.0% of 2026 revenue and the 25 countries below together hold 98.4%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 636 mn | 68.0% | USD 2.0 bn | 12.2% |
| 2 | Germany | USD 47 mn | 5.0% | USD 134 mn | 11.1% |
| 3 | United Kingdom | USD 33 mn | 3.5% | USD 99 mn | 11.7% |
| 4 | France | USD 33 mn | 3.5% | USD 93 mn | 11.0% |
| 5 | Japan | USD 28 mn | 3.0% | USD 78 mn | 10.8% |
| 6 | Italy | USD 23 mn | 2.5% | USD 64 mn | 10.6% |
| 7 | Spain | USD 19 mn | 2.0% | USD 55 mn | 11.4% |
| 8 | Canada | USD 19 mn | 2.0% | USD 55 mn | 11.4% |
| 9 | China | USD 19 mn | 2.0% | USD 70 mn | 14.1% |
| 10 | Netherlands | USD 14 mn | 1.5% | USD 44 mn | 12.0% |
| 11 | Australia | USD 6.0 mn | 0.6% | USD 17 mn | 10.9% |
| 12 | South Korea | USD 4.5 mn | 0.5% | USD 16 mn | 13.5% |
| 13 | Switzerland | USD 4.5 mn | 0.5% | USD 13 mn | 11.0% |
| 14 | Brazil | USD 3.7 mn | 0.4% | USD 13 mn | 13.6% |
| 15 | Belgium | USD 3.7 mn | 0.4% | USD 10 mn | 10.8% |
| 16 | Austria | USD 3.7 mn | 0.4% | USD 10 mn | 10.8% |
| 17 | Sweden | USD 3.0 mn | 0.3% | USD 8.4 mn | 10.9% |
| 18 | Turkey | USD 3.0 mn | 0.3% | USD 10 mn | 13.3% |
| 19 | Israel | USD 3.0 mn | 0.3% | USD 8.4 mn | 10.9% |
| 20 | Denmark | USD 3.0 mn | 0.3% | USD 8.4 mn | 10.9% |
| 21 | India | USD 3.0 mn | 0.3% | USD 13 mn | 15.6% |
| 22 | Saudi Arabia | USD 2.2 mn | 0.2% | USD 7.8 mn | 13.3% |
| 23 | Poland | USD 2.2 mn | 0.2% | USD 7.8 mn | 13.3% |
| 24 | Norway | USD 2.2 mn | 0.2% | USD 6.4 mn | 11.0% |
| 25 | United Arab Emirates | USD 2.2 mn | 0.2% | USD 7.8 mn | 13.3% |
| Rest of world | USD 15 mn | 1.6% | USD 51 mn | 12.7% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Stryker
- Penumbra
- Boston Scientific
Group 2: Regional and specialist players
- AngioDynamics
- Imperative Care
Group 3: Emerging and niche players
- Thrombolex
- Endovascular Engineering
- Magneto Thrombectomy Solutions
- Vetex Medical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the early pulmonary embolism thrombectomy device market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 12.0% is calculated from the resulting values.
The market is divided by technology, by patient risk, by catheter bore, by end user, by operator. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the early pulmonary embolism thrombectomy device market?
The global early pulmonary embolism thrombectomy device market is estimated at USD 820 mn in 2025 and USD 935 mn in 2026.
How fast will the early pulmonary embolism thrombectomy device market grow?
It is forecast to reach USD 2.9 bn by 2036, a compound annual growth rate of 12.0% from 2026, an increase of USD 2.0 bn.
Which country is the largest market for early pulmonary embolism thrombectomy device?
United States is the largest market by revenue at USD 636 mn in 2026, 68.0% of the global total. The three largest countries together hold 76.5%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 14.1% a year from 2026 to 2036.
Which early pulmonary embolism thrombectomy device segment is largest?
In the by technology split, Large-bore mechanical aspiration is the largest segment with 66.0% of 2026 revenue.
Who are the leading early pulmonary embolism thrombectomy device companies?
Global leaders include Stryker, Penumbra, Boston Scientific.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Virus InactivationUSD 935 mn · 10.0% CAGR
- Radiotherapy Positioning DevicesUSD 933 mn · 5.8% CAGR
- Epilepsy Monitoring DevicesUSD 942 mn · 7.5% CAGR
- Robotic Catheterization SystemsUSD 944 mn · 15.0% CAGR
- Glioblastoma Treatment DrugsUSD 945 mn · 5.5% CAGR
- Peptide Receptor Radionuclide Therapy (PRRT)USD 913 mn · 8.0% CAGR
- Biosafety CabinetUSD 958 mn · 7.0% CAGR
- Vaporized Hydrogen Peroxide Sterilization SystemUSD 905 mn · 7.0% CAGR
← Dystrophic Epidermolysis Bullosa Management Elderly-Care & Companion Robots →